Altre lingue Rohto Pharmaceutical Co.,Ltd.

Azioni

4527

JP3982400008

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
3.036 ^JPY	+2,50%		+4,03%	+6,79%

04/04	Mitsui e Rohto acquisteranno l'azienda di farmaci cinesi Eu Yan Sang per 594 milioni di dollari	RE
2023	Le azioni giapponesi chiudono marginalmente in rialzo lunedì, in vista dell'incontro Biden-Xi	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	04/04
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	04/04
Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang	04/04
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang	04/04
Rohto Pharmaceutical Co.,Ltd., Mitsui & Co., Ltd. and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.	04/04
FiNC Technologies Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	28/03
Rohto Pharmaceutical's Profit Climbs 21% in Fiscal Nine Months, Lifts Fiscal-Year Outlook	12/02
Alina Vision Pte Ltd. announced that it has received funding from Fred Hollows Foundation, Rohto Pharmaceutical Co.,Ltd., TVM Capital Healthcare Partners	16/01
Plantex Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd., Dai-ichi Life Holdings, Inc., RealTechJapan LLC.	30/11
Rohto Pharmaceutical Co.,Ltd.(TSE:4527) added to S&P Japan Mid Cap 100	29/11
Japanese Shares Close Marginally Higher Monday Ahead of Biden-Xi Meeting	13/11
Rohto Pharmaceutical’s Attributable Profit Soars 25.8% in Fiscal H1 on Significant Profit Increases Across Categories	13/11
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024	10/11
Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023	10/11
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	10/11
Australis Scientific Pty Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	25/10/23
Butterfly Pea Laboratory Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. and other investors.	02/10/23
Rohto Pharmaceutical’s Attributable Profit Rises 30% in Fiscal Q1 due to Significant Sales Increase	25/08/23
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	09/08/23
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	09/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Rohto Pharmaceutical Co., Ltd: il laboratorio campione dei prodotti da banco

16 marzo 2023 alle 17:20